Cover Image
市場調查報告書

Corcept Therapeutics Incorporated - 產品平台分析

Corcept Therapeutics Incorporated - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 226306
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Corcept Therapeutics Incorporated - 產品平台分析 Corcept Therapeutics Incorporated - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 35 Pages
簡介

Corcept Therapeutics Incorporated是總公司設立於美國的研究型製藥企業,正從事精神疾病及代謝疾病領域的創新治療藥之藥物研發·開發及商品化。正在開發嚴重的心因性憂鬱症等精神疾病,及抗精神病藥造成的體重增加之代謝性疾病的治療藥。

本報告提供Corcept Therapeutics Incorporated的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Corcept Therapeutics Incorporated的基本資料

  • Corcept Therapeutics Incorporated概要
  • 主要資訊
  • 企業資料

Corcept Therapeutics Incorporated:R&D概要

  • 主要的治療範圍

Corcept Therapeutics Incorporated:開發平台分析

  • 各開發階段的開發中產品
  • 單劑產品

Corcept Therapeutics Incorporated:開發中產品概況

  • 後期階段產品開發中產品
    • 第Ⅲ相的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第Ⅰ相的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Corcept Therapeutics Incorporated:藥物簡介

  • mifepristone
  • CORT-125134
  • CORT-113083
  • Small Molecule to Antagonize GR-II receptor for Psychiatric And Metabolic Disorders

Corcept Therapeutics Incorporated:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Corcept Therapeutics Incorporated:最近的開發平台資訊

Corcept Therapeutics Incorporated:暫停開發中的計劃

Corcept Therapeutics Incorporated:開發中止的開發中產品

Corcept Therapeutics Incorporated:企業理念

Corcept Therapeutics Incorporated:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07130CDB

Summary

Global Markets Direct's, 'Corcept Therapeutics Incorporated - Product Pipeline Review - 2015', provides an overview of the Corcept Therapeutics Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Corcept Therapeutics Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Corcept Therapeutics Incorporated including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Corcept Therapeutics Incorporated's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Corcept Therapeutics Incorporated's pipeline products

Reasons to buy

  • Evaluate Corcept Therapeutics Incorporated's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Corcept Therapeutics Incorporated in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Corcept Therapeutics Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Corcept Therapeutics Incorporated and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Corcept Therapeutics Incorporated
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Corcept Therapeutics Incorporated and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Corcept Therapeutics Incorporated Snapshot
    • Corcept Therapeutics Incorporated Overview
    • Key Information
    • Key Facts
  • Corcept Therapeutics Incorporated - Research and Development Overview
    • Key Therapeutic Areas
  • Corcept Therapeutics Incorporated - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Corcept Therapeutics Incorporated - Pipeline Products Glance
    • Corcept Therapeutics Incorporated - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Corcept Therapeutics Incorporated - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Corcept Therapeutics Incorporated - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Corcept Therapeutics Incorporated - Drug Profiles
    • mifepristone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CORT-125134
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CORT-113083
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize GR-II receptor for Psychiatric And Metabolic Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Corcept Therapeutics Incorporated - Pipeline Analysis
    • Corcept Therapeutics Incorporated - Pipeline Products by Target
    • Corcept Therapeutics Incorporated - Pipeline Products by Route of Administration
    • Corcept Therapeutics Incorporated - Pipeline Products by Molecule Type
    • Corcept Therapeutics Incorporated - Pipeline Products by Mechanism of Action
  • Corcept Therapeutics Incorporated - Recent Pipeline Updates
  • Corcept Therapeutics Incorporated - Dormant Projects
  • Corcept Therapeutics Incorporated - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • mifepristone
  • Corcept Therapeutics Incorporated - Company Statement
  • Corcept Therapeutics Incorporated - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Corcept Therapeutics Incorporated, Key Information
  • Corcept Therapeutics Incorporated, Key Facts
  • Corcept Therapeutics Incorporated - Pipeline by Indication, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Stage of Development, 2015
  • Corcept Therapeutics Incorporated - Monotherapy Products in Pipeline, 2015
  • Corcept Therapeutics Incorporated - Pre-Registration, 2015
  • Corcept Therapeutics Incorporated - Phase I, 2015
  • Corcept Therapeutics Incorporated - Preclinical, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Target, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Route of Administration, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Molecule Type, 2015
  • Corcept Therapeutics Incorporated - Pipeline Products by Mechanism of Action, 2015
  • Corcept Therapeutics Incorporated - Recent Pipeline Updates, 2015
  • Corcept Therapeutics Incorporated - Dormant Developmental Projects,2015
  • Corcept Therapeutics Incorporated - Discontinued Pipeline Products, 2015

List of Figures

  • Corcept Therapeutics Incorporated - Pipeline by Top 10 Indication, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Stage of Development, 2015
  • Corcept Therapeutics Incorporated - Monotherapy Products in Pipeline, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Top 10 Target, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Top 10 Route of Administration, 2015
  • Corcept Therapeutics Incorporated - Pipeline by Top 10 Molecule Type, 2015
  • Corcept Therapeutics Incorporated - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top